Autologous CD22 CAR T Cells Following Commercial CD19 CAR T Cells in B Cell Malignancies

Recruiting

Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.

Trial locations(1 site)

United States

Stanford University, Palo Alto, California